JUN 09, 2021 4:12 PM PDT

New Drug Prevents Dementia After Head Injury

WRITTEN BY: Annie Lennon

Researchers led by the University of South Australia have identified a new drug that may be able to help prevent athletes from developing dementia following repeated head injuries. 

Chronic traumatic encephalopathy (CTE) is a progressive and fatal brain disease linked to the accumulation of a protein known as hyperphosphorylated tau. The build-up of this protein in the brain affects cognition and behavior. The condition is a form of head injury-associated dementia. 

As a rationale for the development of the new drug, the researchers say that after a head injury, the brain releases a neurotransmitter called substance P. This neurotransmitter is known to modulate pain perception. It also plays a role in the secondary injury process after traumatic brain injury, particularly in neuroinflammation, increased blood-brain barrier permeability and edema formation, which has been linked to increased intracranial pressure. 

In the case of CTE, substance P has also been linked to increased amounts of tau protein that collect inside neurons. This build-up leads to memory problems, confusion, changes in personality, aggressive behavior, depressive mood and suicidal thoughts. 

For the current study, the researchers used a drug known as a Neurokinin-1 (NK-1) receptor antagonist to block substance P in animal models of CTE. In doing so, they were able to prevent tau protein tangles from developing in the brain and leading to neurological problems. 

The researchers now hope that CTE could be prevented via the same mechanism in humans. Bob Vink, the lead author of the study, now hopes to progress the treatment into human clinical trials, where it may be able to aid athletes who play contact sports including boxers and footballers, as well as military veterans who sustain head injuries during conflict. He said however that this may take several years as currently, CTE can only be diagnosed post-mortem. 

 

Sources: University of South AustraliaScientific Reports 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 28, 2022
Cannabis Sciences
Are Cannabis Users Nicer?
JUL 28, 2022
Are Cannabis Users Nicer?
A study published in Nature offers evidence that cannabis has a positive effect on the psychosocial health of young adul ...
JUL 08, 2022
Cannabis Sciences
The Latest Research on Cannabis Social Equity Programs
JUL 08, 2022
The Latest Research on Cannabis Social Equity Programs
Cannabis social equity programs are designed to increase licensure and employment opportunities for lower income and BIP ...
JUL 13, 2022
Neuroscience
Listen Up: Sound Provides Pain Relief
JUL 13, 2022
Listen Up: Sound Provides Pain Relief
People often think of pharmaceutical treatments and meditation to ease physical pain, but pain can be alleviated with mu ...
AUG 11, 2022
Clinical & Molecular DX
New Tuberculosis Vaccine Enters Phase III Clinical Trial
AUG 11, 2022
New Tuberculosis Vaccine Enters Phase III Clinical Trial
Tuberculosis is a disease caused by the bacterium Mycobacterium tuberculosis. It is spread through the air when a person ...
AUG 30, 2022
Clinical & Molecular DX
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
AUG 30, 2022
Caffeine Metabolite Could Slow Progression of Nearsightedness in Children
Myopia, also known as nearsightedness, is a common vision condition in which objects far away appear blurry. Myopia occu ...
AUG 30, 2022
Cannabis Sciences
Research Highlights the Training Needs of Cannabis Dispensary Staff
AUG 30, 2022
Research Highlights the Training Needs of Cannabis Dispensary Staff
A new study published in JCO Oncology Practice, and conducted by researchers at Dana-Farber Cancer Institute, found unev ...
Loading Comments...